香港股市 已收市

bioAffinity Technologies, Inc. (BIAFW)

NasdaqCM - NasdaqCM 延遲價格。貨幣為 USD。
加入追蹤清單
0.5900+0.1200 (+25.53%)
收市:04:00PM EDT

bioAffinity Technologies, Inc.

22211 West Interstate 10
Suite 1206
San Antonio, TX 78257
United States
210 698 5334
https://www.bioaffinitytech.com

版塊Healthcare
行業Diagnostics & Research
全職員工

高階主管

名稱頭銜支付行使價出生年份
Mr. Steven GirgentiFounder & Executive Chairman of the Board113.75k1946
Ms. Maria Zannes J.D.Founder, President, CEO & Director299.17k1956
Mr. Michael Dougherty CPA, M.B.A.VP & CFO238.92k1979
Mr. Xavier T. Reveles M.S.Chief Operating Officer1970
Dr. Vivienne I. Rebel M.D., Ph.D.Executive VP and Chief Medical & Science Officer238.39k1966
Mr. Timothy P. Zannes J.D.Executive VP, Secretary & General Counsel1953
Ms. Julie Anne OvertonDirector of Communications
Mr. Dallas J. ColemanNational Director of Sales
Dr. William Bauta Ph.D.Senior Vice President of Therapeutics
截止 2023年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.

公司管治

截至 無 止,bioAffinity Technologies, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。